Cancer Research Cancer Epigenetics  EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kedei, N.
Right arrow Articles by Blumberg, P. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kedei, N.
Right arrow Articles by Blumberg, P. M.
[Cancer Research 64, 3243-3255, May 1, 2004]
© 2004 American Association for Cancer Research


Regular Articles

Characterization of the Interaction of Ingenol 3-Angelate with Protein Kinase C

Noemi Kedei1, Daniel J. Lundberg1, Attila Toth1, Peter Welburn3, Susan H. Garfield2 and Peter M. Blumberg1

1 Laboratory of Cellular Carcinogenesis and Tumor Promotion, and 2 Laboratory of Experimental Carcinogenesis, National Cancer Institute, Bethesda, Maryland, and 3 Peplin Biotech, Fortitude Valley, Queensland, Australia

Ingenol 3-angelate (I3A) is one of the active ingredients in Euphorbia peplus, which has been used in traditional medicine. Here, we report the initial characterization of I3A as a protein kinase C (PKC) ligand. I3A bound to PKC-{alpha} in the presence of phosphatidylserine with high affinity; however, under these assay conditions, little PKC isoform selectivity was observed. PKC isoforms did show different sensitivity and selectivity for down-regulation by I3A and phorbol 12-myristate 13-acetate (PMA) in WEHI-231, HOP-92, and Colo-205 cells. In all of the three cell types, I3A inhibited cell proliferation with somewhat lower potency than did PMA. In intact CHO-K1 cells, I3A was able to translocate different green fluorescent protein-tagged PKC isoforms, visualized by confocal microscopy, with equal or higher potency than PMA. PKC-{delta} in particular showed a different pattern of translocation in response to I3A and PMA. I3A induced a higher level of secretion of the inflammatory cytokine interleukin 6 compared with PMA in the WEHI-231 cells and displayed a marked biphasic dose-response curve for the induction. I3A was unable to cause the same extent of association of the C1b domain of PKC-{delta} with lipids, compared with PMA or the physiological regulator diacylglycerol, and was able to partially block the association induced by these agents, measured by surface plasmon resonance. The in vitro kinase activity of PKC-{alpha} induced by I3A was lower than that induced by PMA. The novel pattern of behavior of I3A makes it of great interest for further evaluation.




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
M. Serova, A. Ghoul, K. A. Benhadji, S. Faivre, C. Le Tourneau, E. Cvitkovic, F. Lokiec, J. Lord, S. M. Ogbourne, F. Calvo, et al.
Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells
Mol. Cancer Ther., April 1, 2008; 7(4): 915 - 922.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. M. Challacombe, A. Suhrbier, P. G. Parsons, B. Jones, P. Hampson, D. Kavanagh, G. E. Rainger, M. Morris, J. M. Lord, T. T. T. Le, et al.
Neutrophils Are a Key Component of the Antitumor Efficacy of Topical Chemotherapy with Ingenol-3-Angelate
J. Immunol., December 1, 2006; 177(11): 8123 - 8132.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Pu, M. L. Peach, S. H. Garfield, S. Wincovitch, V. E. Marquez, and P. M. Blumberg
Effects on Ligand Interaction and Membrane Translocation of the Positively Charged Arginine Residues Situated along the C1 Domain Binding Cleft in the Atypical Protein Kinase C Isoforms
J. Biol. Chem., November 3, 2006; 281(44): 33773 - 33788.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S.-J. Cozzi, P. G. Parsons, S. M. Ogbourne, J. Pedley, and G. M. Boyle
Induction of Senescence in Diterpene Ester-Treated Melanoma Cells via Protein Kinase C-Dependent Hyperactivation of the Mitogen-Activated Protein Kinase Pathway.
Cancer Res., October 15, 2006; 66(20): 10083 - 10091.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. Hampson, H. Chahal, F. Khanim, R. Hayden, A. Mulder, L. K. Assi, C. M. Bunce, and J. M. Lord
PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC
Blood, August 15, 2005; 106(4): 1362 - 1368.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. C. Braun, S. H. Garfield, and P. M. Blumberg
Analysis by Fluorescence Resonance Energy Transfer of the Interaction between Ligands and Protein Kinase C{delta} in the Intact Cell
J. Biol. Chem., March 4, 2005; 280(9): 8164 - 8171.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.